Metacrine, Inc.
3985 Sorrento Valley Blvd
Suite C
San Diego
CA
92121
United States
Website: http://www.metacrine.com/
About Metacrine, Inc.
We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully designed MET409, our lead product candidate, to be an optimized, next-generation FXR agonist that we are initially developing as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease. Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.
58 articles about Metacrine, Inc.
-
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
12/23/2022
Equillium, Inc. and Metacrine, Inc. announced the mutual termination of their previously announced definitive merger agreement.
-
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
12/23/2022
Metacrine, Inc. and Equillium, Inc. announced the mutual termination of their previously announced definitive merger agreement.
-
Metacrine Reports Third-Quarter 2022 Results
11/14/2022
Metacrine, Inc., a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, reported its third-quarter 2022 financial results.
-
Equillium to Acquire Metacrine in All-Stock Transaction
9/6/2022
Equillium, Inc. and Metacrine Inc., announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction.
-
Metacrine Reports Second-Quarter 2022 Results
8/9/2022
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, reported its second-quarter 2022 financial results.
-
Metacrine Reports First-Quarter 2022 Results
5/12/2022
Metacrine, Inc. reported its first-quarter 2022 financial results and provided a business update.
-
Metacrine Reports Fourth-Quarter 2021 Results
3/30/2022
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, reported its fourth-quarter 2021 financial results.
-
Metacrine Announces Executive Leadership Changes
2/24/2022
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, announced that Ms. Trisha Millican has resigned her position as chief financial officer.
-
Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
2/11/2022
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis.
-
BioSpace Movers & Shakers, Dec. 31
12/31/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Metacrine Announces Resignation of Chief Medical Officer
12/27/2021
Metacrine, Inc. today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity.
-
Metacrine Reports Third-Quarter 2021 Results
11/11/2021
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, reported its third-quarter 2021 financial results.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
11/2/2021
Metacrine, Inc. today reported topline results from its Phase 2a trial evaluating MET409
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
10/21/2021
Metacrine, Inc. (NASDAQ:MTCR), today reported interim results from a Phase 2a clinical trial evaluating the efficacy and safety of MET642, a farnesoid X receptor (FXR) agonist, in approximately 60 non-alcoholic steatohepatitis (NASH) patients after 16 weeks of treatment.
-
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
9/9/2021
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced that it has completed enrollment for its Phase 2a trial evaluating MET642, an optimized farnesoid X receptor agonist, in patients with non-alcoholic steatohepatitis.
-
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
9/8/2021
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET.
-
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Metacrine, Inc. today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021.
-
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
8/12/2021
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.